|
Post by beardawg on Nov 21, 2014 8:15:32 GMT -5
My guess is that the 2 Phase launch is to first get data to change the label while still making money, then the second launch is to coincide with the Toujeo launch. They have said all along that they will partner Afrezza with Toujeo. This method gives them time to see the demand, build lines to support it, then be prepared for a second launch as a compliment to Toujeo, *with the new label*, possibly advertised as a treatment that is virtually free of hypos.
Sounds like a plan, but I think it will do even better than they expect and will possibly be on par with Toujeo/Lantus (I'm going to stop spelling that out), when it starts being used outside the traditional injected prandial use.
|
|
|
Post by ezrasfund on Nov 21, 2014 9:45:19 GMT -5
They can only sell as much as they make, so sales ramp up will not be too fast in the beginning. Also I think they will go after the low hanging fruit first, which it seems they have identified as needle and hypo phobic Type 2's who resist beginning insulin therapy or stop after experiencing a severe hypo. Of course they will also be switching Type 1's to Afrezza, but it will be word of mouth among doctors and patients that spreads the info about Afrezza's superior PK/PD advantages in advance of any label changes.
|
|
|
Post by babaoriley on Nov 21, 2014 17:48:11 GMT -5
All this talk about low hanging fruit and not one lunch, but two, is really making me hungry. I love lunch, and would warm to the idea of a second lunch. Maybe 11am and 2pm? Not sure, but it sure sounds great. Not only are you eating during lunch, but you're not at work being pestered!
Our RN's can tell you how much I love lunch!
What? Launch......?
Nevermind.
|
|